Edoxaban – Medxy AI

Win Ratio Analysis Confirms No Net Benefit for Anticoagulation in Device-Detected Atrial Fibrillation

By MedXY 01/03/2026

A hierarchical win ratio analysis of the NOAH-AFNET 6 trial confirms that edoxaban does not provide a net clinical benefit over no anticoagulation in patients with device-detected atrial fibrillation, primarily due to the balance between low stroke rates and significant bleeding risks.

Cardiology news Specialties

Higher Risk of Major Gastrointestinal Bleeding with Edoxaban vs Warfarin After TAVR: Insights from the ENVISAGE-TAVI AF Trial

By MedXY 08/17/2025

The ENVISAGE-TAVI AF trial found that patients with atrial fibrillation undergoing TAVR had a higher incidence of major gastrointestinal bleeding when treated with edoxaban compared to warfarin, highlighting the importance of risk factor identification.

Cardiology Specialties

Edoxaban as a Safe and Effective Anticoagulant Early After Bioprosthetic Valve Replacement: Insights from the ENBALV Trial

By MedXY 08/17/2025

The ENBALV randomized trial demonstrates that edoxaban offers a potential safe and efficacious alternative to warfarin for anticoagulation within three months after surgical bioprosthetic valve replacement, with comparable thromboembolic event rates and a distinct safety profile.